The effects of ProAlgaZyme novel algae infusion on metabolic syndrome and markers of cardiovascular health

Background: Metabolic Syndrome, or Syndrome X, is characterized by a set of metabolic and lipid imbalances that greatly increases the risk of developing diabetes and cardiovascular disease. The syndrome is highly prevalent in the United States and worldwide, and treatments are in high demand. ProAlgaZyme, a novel and proprietary freshwater algae infusion in purified water, has been the subject of several animal studies and has demonstrated low toxicity even with chronic administration at elevated doses. The infusion has been used historically for the treatment of several inflammatory and immune disorders in humans and is considered well-tolerated. Here, the infusion is evaluated for its effects on the cardiovascular risk factors present in metabolic syndrome in a randomized double-blind placebocontrolled study involving 60 overweight and obese persons, ages 25–60. All participants received four daily oral doses (1 fl oz) of ProAlgaZyme (N = 22) or water placebo (N = 30) for a total of 10 weeks, and were encouraged to maintain their normal levels of physical activity. Blood sampling and anthropometric measurements were taken at the beginning of the study period and after 4, 8 and 10 weeks of treatment. Eight participants did not complete the study. Results: ProAlgaZyme brought about statistically significant (p < 0.001) reductions in the following: weight, body fat, total cholesterol, LDL-cholesterol, triglycerides, C-reactive protein and fasting blood glucose levels, accompanied by a significant (p < 0.001) increase in HDL-cholesterol levels over the 10week study period. The infusion was well-tolerated and no side effects were noted. Conclusion: ProAlgaZyme (4 fl oz daily) consumption resulted in significant reductions in weight and blood glucose levels, while significantly improving serum lipid profiles and reducing markers of inflammation, thus improving cardiovascular risk factors in overweight and obese subjects over a course of 10 weeks with an absence of adverse side effects. Trial Registration: US ClinicalTrials.gov NCT00489333 Published: 5 September 2007 Lipids in Health and Disease 2007, 6:20 doi:10.1186/1476-511X-6-20 Received: 12 June 2007 Accepted: 5 September 2007 This article is available from: http://www.lipidworld.com/content/6/1/20 © 2007 Oben et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

[1]  G. Agbor,et al.  Medicinal plants can be good source of antioxidants: case study in Cameroon. , 2007, Pakistan journal of biological sciences : PJBS.

[2]  Morihiro Matsuda,et al.  Increased oxidative stress in obesity and its impact on metabolic syndrome. , 2004, The Journal of clinical investigation.

[3]  D. Taillandier,et al.  Glucocorticoids regulate mRNA levels for subunits of the 19 S regulatory complex of the 26 S proteasome in fast-twitch skeletal muscles. , 2004, The Biochemical journal.

[4]  Claude Lenfant,et al.  Definition of Metabolic Syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association Conference on Scientific Issues Related to Definition , 2004, Arteriosclerosis, thrombosis, and vascular biology.

[5]  P. Tebas,et al.  Management of chronic hepatitis B in an HIV-positive patient with 3TC-resistant hepatitis B virus. , 2003, AIDS patient care and STDs.

[6]  J. Cristol,et al.  Immunoturbidimetric Determination of C-Reactive Protein (CRP) and High-Sensitivity CRP on Heparin Plasma. Comparison with Serum Determination , 2003, Clinical chemistry and laboratory medicine.

[7]  J. Strong,et al.  Obesity Accelerates the Progression of Coronary Atherosclerosis in Young Men , 2002, Circulation.

[8]  L. Groop,et al.  Cardiovascular morbidity and mortality associated with the metabolic syndrome. , 2001, Diabetes care.

[9]  Bruce M. Spiegelman,et al.  Obesity and the Regulation of Energy Balance , 2001, Cell.

[10]  J. Flier,et al.  Obesity and insulin resistance. , 2000, The Journal of clinical investigation.

[11]  A. Dulloo,et al.  Green tea and thermogenesis: interactions between catechin-polyphenols, caffeine and sympathetic activity , 2000, International Journal of Obesity.

[12]  A. Dulloo,et al.  Efficacy of a green tea extract rich in catechin polyphenols and caffeine in increasing 24-h energy expenditure and fat oxidation in humans. , 1999, The American journal of clinical nutrition.

[13]  T. Funahashi,et al.  Molecular Mechanism of Metabolic Syndrome X: Contribution of Adipocytokines · Adipocyte‐derived Bioactive Substances , 1999, Annals of the New York Academy of Sciences.

[14]  James W. Anderson,et al.  Meta-analysis of the effects of soy protein intake on serum lipids. , 1995, The New England journal of medicine.

[15]  A. Waterhouse,et al.  Principal Phenolic Phytochemicals in Selected California Wines and Their Antioxidant Activity in Inhibiting Oxidation of Human Low-Density Lipoproteins , 1995 .

[16]  F. Kelly,et al.  Evidence for Increased oxidative Damage in Patients with Cystic Fibrosis , 1994, Pediatric Research.

[17]  P. Steiner,et al.  Plasma high-density lipoprotein cholesterol concentrations determined after removal of other lipoproteins by heparin/manganese precipitation or by ultracentrifugation. , 1976, Clinical chemistry.

[18]  W. Richmond Preparation and properties of a cholesterol oxidase from Nocardia sp. and its application to the enzymatic assay of total cholesterol in serum. , 1973, Clinical chemistry.

[19]  G Bucolo,et al.  Quantitative determination of serum triglycerides by the use of enzymes. , 1973, Clinical chemistry.

[20]  R. Levy,et al.  Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. , 1972, Clinical chemistry.

[21]  P. Trinder Determination of Glucose in Blood Using Glucose Oxidase with an Alternative Oxygen Acceptor , 1969 .

[22]  G. Agbor,et al.  The use of a Cissus quadrangularis formulation in the management of weight loss and metabolic syndrome , 2006, Lipids in Health and Disease.

[23]  J. German,et al.  Inhibition of in vitro human LDL oxidation by phenolic antioxidants from grapes and wines , 1996 .

[24]  E. Frankel,et al.  Natural antioxidants in grapes and wines , 1994 .